Nanobiotix S.A. (NBTX) Financial Analysis & Valuation | Quarter Chart
Nanobiotix S.A. (NBTX)
NBTXPrice: $31.83
Fair Value: 🔒
🔒score
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, l... more
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the tr... more
Description
Shares
| Market Cap | $1.54B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | FR | CEO | Anne-Juliette Hermant |
| IPO Date | 2020-12-11 | CAGR | 0.25% |
| Employees | 108 | Website | www.nanobiotix.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NBTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.09B | P/E Ratio | -54.88 |
| Forward P/E | 512.97 | PEG Ratio | — |
| P/S Ratio | 54.03 | P/B Ratio | -18.59 |
| P/CF Ratio | -46.97 | P/FCF Ratio | -47.17 |
| EPS | $-0.58 | EPS Growth 1Y | -29.45% |
| EPS Growth 3Y | -50.26% | EPS Growth 5Y | 1.04% |
| Revenue Growth 1Y | -53.27% | Gross Margin | 1% |
| Operating Margin | -0.36% | Profit Margin | -0.81% |
| ROE | 0.31% | ROA | -0.35% |
| ROCE | -1.06% | Current Ratio | 1.09 |
| Quick Ratio | 1.09 | Cash Ratio | 0.92 |
| Debt/Equity | -1.13 | Interest Coverage | -1.04 |
| Altman Z Score | 1.67 | Piotroski Score | 1 |